Testing genes in prostate cancer after radiation relapse
Part of Cancer, Kidney & urinary clinical trials.
This study looks at specific gene changes (TMPRSS2-ERG fusion and PTEN deletion) in people whose prostate cancer returned after radiation. It aims to understand who may have a higher risk of relapse and help predict outcomes after salvage or radical radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer is at least stage T3a
- Your PSA blood test is higher than 20
- Your biopsy results show Gleason score 8 or higher
- You are able to do daily activities, with a Karnofsky score of 70 or more
- You agree to sign the study consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a targeted scan (PSMA PET/CT) can help doctors choose the best “salvage” radiation treatment when prostate cancer comes back by PSA blood tests after surgery. It may help some people avoid under- or over-treating the areas where the cancer is returning.
This trial looks at long-term results after radiation therapy for prostate cancer. By studying PSA test results and imaging scans from men who were treated at least 10 years ago, researchers hope to learn more about side effects and how well the treatment worked over time.
This trial tests how well salvage radiation therapy works for prostate cancer that has come back after surgery. It looks at whether adding hormone therapy based on PSA response improves outcomes.
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
This trial compares two different radiation schedules to treat prostate cancer that returned based on rising PSA blood tests after prostatectomy (prostate removal). If you qualify, it may help you and your team choose a radiation approach with the goal of controlling PSA relapse.
This study tests an “early salvage” approach using radiotherapy after prostate cancer surgery when PSA starts rising again. It aims to see whether earlier treatment (chosen based on higher-risk features) can improve outcomes for people who did not take immediate extra therapy after surgery.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.